There you go. What great timing. This deal keeps getting better and better. This should be another trigger in the merger agreement but I bet it isn't.
NEW YORK (TheStreet) -- Opko Health (NYSE:OPK) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.
This is a garbage downgrade but I seriously hope either another analyst steps up with a real one or the company does something to counter this because the timing and the optics just add fuel to this mess they have created.
You R right, it is a garbage downgrade, and four hours later the street comes out and says opk is in over sold territory and one should consider an entry point. The earnings per share and every other metric has not changed since they initiated their buy rating, there has been no earnings release since then.
You think opk bid too low for pbth, the current opko price action says otherwise. The market thinks it a bad deal for opko, that is why the weakness. Of course you will say OPK is a house of cards with no value, price inflated by Frost, etc., regardless of their 3 phase 3 candidates, but that is what makes a
How many Employees does Opko have around the globe??? How many countries are they doing business in??? What is their Y/Y revenue growth??? How large is their patent library??? How many partnerships and licensing agreements does OPK have, how many companies does opk own stock in??? A house of cards? Or a stacked deck? Frost has made the 2nd most money in biotech in US history, but you know more.